Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Experimental Oncology
  • Published:

Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines

Abstract

Four human cell lines derived from malignant gliomas were immunohistochemically examined for their content of estramustine-binding protein (EMBP). EMBP was detected in a large amount in all glioma cells during the entire cell cycle. EMBP has previously been demonstrated to be the major receptor protein in prostatic cancers for the cytostatic drug estramustine-phosphate (EMP). EMP caused a dose-dependent inhibition of exponentially growing cells by increasing the number of cells in G2/M stage of the cell cycle as monitored by flow cytofluorometry. The effect may be coupled to arrest of the glioma cells at metaphase. The presence of EMBP may suggest a selective binding and effect of EMP in glioma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Schoultz, E., Lundblad, D., Bergh, J. et al. Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer 58, 326–329 (1988). https://doi.org/10.1038/bjc.1988.212

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.212

This article is cited by

Search

Quick links